> "The median per-drug R&D spending of companies that developed more than six drugs – that’s only 8 companies – was $5.8 billion."
...so that is $5-6B USD per drug DEVELOPED in large companies.
Gilead - maker of Sovaldi/Harvoni for HepC treatment - has been on a development tear of late, and almost certainly falls into that range IMO [2].
For companies that produce fewer drugs - the estimates are between $700M-$1B per drug.
Note these are prices for drug R&D only ("development") - there is no guarantee those drugs developed make it to market ("approval") - Over 90% do not.
edit: source links
1 - https://www.forbes.com/sites/matthewherper/2017/10/16/the-co...
2 - https://en.wikipedia.org/wiki/Gilead_Sciences#2010_to_2019